慢性淋巴细胞白血病患者COVID-19 pandemic结局:聚焦极早期阶段与Omicron时代
瑞典全国性登记研究比较慢性淋巴细胞白血病(CLL)患者与普通人群在COVID-19大流行极早期及Omicron时代的重症与死亡风险。共纳入2 088 163例首次SARS-CoV-2感染(CLL 1289例),CLL患者90天全因死亡率在野生型、Alpha、Delta和Omicron期分别为24.8%、17.2%、4.1%和12.6%,调整相对风险在Omicron期为1.49(95%CI 1.24-1.78)。斯德哥尔摩2020年前6个月CLL患者死亡率较2019年升高55%。
要点
- CLL患者Omicron期90天全因死亡率随年龄升高:<65岁0.6%、65-74岁5.4%、≥75岁19.7%。
- Omicron期CLL患者调整相对风险为1.49(95%CI 1.24-1.78),重症和死亡风险仍显著增加。
- 小分子抑制剂(aRR 1.56,95%CI 1.03-2.37)和糖皮质激素使用(aRR 1.45,95%CI 1.04-2.02)与死亡率升高相关。
核心结论
- 瑞典CLL患者在COVID-19大流行极早期和Omicron时代均观察到重症和死亡风险显著增加,尤其在大流行初期国家防护措施较少时。
研究设计与样本
- 瑞典全国性登记研究,使用10个国家登记数据库,比较1930至2003年出生人群中CLL患者与非CLL个体经PCR确诊的SARS-CoV-2感染至2023年2月的重症COVID-19结局。
- 总人群8 275 839例(CLL 6653例),纳入2 088 163例首次感染(CLL 1289例)。
- 另分析首都斯德哥尔摩2020年前6个月与2019年同期CLL患者全因死亡率变化。
主要发现
- CLL患者90天全因死亡率:野生型24.8%(aRR 1.95,95%CI 1.58-2.41)、Alpha 17.2%(aRR 2.38,95%CI 1.58-3.57)、Delta 4.1%(aRR 0.71,95%CI 0.24-2.08)、Omicron 12.6%(aRR 1.49,95%CI 1.24-1.78)。
- Omicron期CLL患者死亡率:<65岁0.6%、65-74岁5.4%、≥75岁19.7%。
- 小分子抑制剂使用(aRR 1.56,95%CI 1.03-2.37)和糖皮质激素使用(aRR 1.45,95%CI 1.04-2.02)与死亡率升高相关。
- 斯德哥尔摩2020年前6个月CLL患者全因死亡率较2019年同期升高55%;截至6月30日年龄和性别调整相对风险CLL患者为1.53(95%CI 1.09-2.15,P = .02),普通人群为1.29(95%CI 1.25-1.33,P < .001)。
临床怎么用
- 作者强调需要为CLL患者制定更主动的大流行应对策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with chronic lymphocytic leukemia (CLL) face an increased risk for severe COVID-19. This study from Sweden, a country that only had a few mandatory restrictions at the onset of the pandemic, used 10 nationwide registers to compare the risks for severe COVID-19 outcomes of polymerase chain reaction-verified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections through February 2023 in individuals with and those without CLL. From a population of 8 275 839 (6653 CLL) individuals born between 1930 and 2003, 2 088 163 first infections (1289 CLL) were included. The 90-day all-cause mortality rate and adjusted relative risk (aRR; 95% confidence interval) for individuals with CLL vs the general population was 24.8% (1.95; 1.58-2.41) during wild-type, 17.2% (2.38; 1.58-3.57) during Alpha, 4.1% (0.71; 0.24-2.08) during Delta, and 12.6% (1.49; 1.24-1.78) during Omicron infections. Their mortality during Omicron was 0.6% (<65 years), 5.4% (65-74 years), and 19.7% (≥75 years). Small molecule inhibitors (1.56; 1.03-2.37) and corticosteroid usage (1.45; 1.04-2.02) was associated with increased mortality. Next, we analyzed the all-cause mortality in the capital (Stockholm), widely affected by SARS-CoV-2 at the onset of the pandemic. Mortality in individuals with CLL increased by 55% during the first 6 months of 2020 vs 2019, and the age- and sex-aRR by 30 June was 1.53 (1.09-2.15) for individuals with CLL (P = .02) and 1.29 (1.25-1.33) for the general population (P < .001). Collectively, a significantly increased risk for severe COVID-19 and death was observed among individuals with CLL in Sweden, particularly at the onset of the pandemic when few national protective measures were introduced and also after Omicron emerged, emphasizing the need for a more pro-active pandemic strategy for CLL.
引用
- Hedberg P, Blixt L, Eketorp Sylvan S, et al. Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era. Blood Adv. 2025. PMID: 39983071. doi:10.1182/bloodadvances.2024015260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。